Contrast-associated acute kidney injury (CA-AKI) is a known complication of endovascular procedures using an iodinated contrast medium (ICM), especially in patients with peripheral artery disease (PAD) and chronic kidney disease (CKD). This retrospective study evaluated the incidence and risk factors of AKI in patients with PAD and CKD undergoing diagnostic angiography or endovascular intervention using carbon dioxide (CO2) as the primary contrast medium, with optional bailout ICM use. We included 340 patients who underwent peripheral angiography or intervention between September 2014 and December 2020. CO2 was used as the primary contrast medium for all patients, as the majority were classified with advanced CKD stages 3–5 according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. Bailout ICM was used in 80% of cases (mean 21.23 ± 14.09 mL). Postinterventional AKI occurred in 13.2% of patients, with over 70% classified as stage 1. Seven patients required new dialysis within 7 days. Multivariate analysis identified hypertension, heart failure, and coronary artery disease as independent AKI risk factors. Statin or Renin–Angiotensin–Aldosteron System (RAAS) inhibitor use and higher pre-interventional GFR were protective. AKI remains common in patients undergoing CO2-guided peripheral procedures. Further studies are needed to explore underlying mechanisms and outcomes.
This proof-of-concept study aimed to assess the feasibility of Multispectral Optoacoustic Tomography (MSOT) in evaluating changes in oxygenated hemoglobin (HbO2) levels in muscles of the lower limb before and after lower extremity revascularization (LER). In 26 patients, HbO2 levels were assessed before and after LER, with follow-up assessing symptom control and patency for up to six months. A significant difference in HbO2 levels was observed between pre- and post-LER in the muscles of the lower limb. In 10 patients, HbO2 levels did not increase following LER, and at the 6-month follow-up, 2 of these patients required target lesion revascularization (TLR) due to restenosis of ≥ 50 % stenosis. In contrast, 16 patients demonstrated increased HbO2 levels post-LER, with no patients requiring TLR at 6-months. This study demonstrates the potential of MSOT to detect changes in tissue perfusion following LER, highlighting its promise as a novel imaging modality for guiding treatment strategies.
Demographic shifts have increased the complexity of endovascular therapy, often resulting in painful procedures. Local anesthesia (LA) has become a viable alternative to general anesthesia for high-risk patients undergoing endovascular therapy. A 76-year-old woman presented with severe claudication due to a heavily calcified chronic total occlusion of the superficial femoral artery. After initial subintimal guidewire passage, re-entry into the distal true lumen was achieved using a BeBack crossing catheter. During consecutive balloon inflation, the patient experienced severe discomfort. To improve patient compliance and facilitate balloon dilation of adequate diameter, local infiltration of lidocaine and iodinated contrast medium was administered via the BeBack crossing catheter in the perivascular space along the superficial femoral artery. The procedure was then successfully completed. The injection of LA via the BeBack crossing catheter provided targeted pain management, ensuring patient compliance without extending procedure duration or requiring additional percutaneous LA administration. LA is a feasible alternative to general anesthesia for high-risk patients undergoing lower limb revascularization of complex lesions and total occlusions. In clinical cases where a BeBack crossing catheter is already in use, using the catheter for perivascular anesthesia injection offers effective pain management peri-interventionally.
Objective: To evaluate the long-term safety and efficacy of the pave-and-crack technique, combining aggressive balloon dilatation and covered stent implantation, for endovascular therapy (EVT) of highly calcified femoropopliteal chronic total occlusions (CTOs) in poor surgical candidates unsuitable for open revascularization or conventional EVT. Design: Single-center retrospective cohort study based on a prospectively maintained peripheral artery disease database. Methods: Patients with symptomatic femoropopliteal CTOs treated using the pave-and-crack technique between September 2014 and April 2025 were included. Lesion and procedural characteristics, technical success, defined as residual stenosis ≤ 30%, complications, major target limb amputation, and symptom status were assessed. Kaplan–Meier analysis was used to estimate freedom from target lesion revascularization (TLR) and all-cause mortality through 5 years. Results: A total of 122 patients with 136 femoropopliteal CTOs were treated. Mean lesion length was 253.0 ± 90.1 mm, and 93.4% (127/136) of lesions were severely calcified. Retrograde access was required in 72.8% (99/136) of procedures. Technical success was achieved in 93.4% (127/136). Freedom from target lesion revascularization was 91.4% ± 2.6% at 1 year, 77.9% ± 4.6% at 3 years, and 66.7% ± 7.2% at 5 years. Major target limb amputation occurred in four cases presenting with CLTI (8.5%; 4/47) and none with claudication (0%; 0/89). Five-year freedom from all-cause mortality was 71.4 ± 6.9% for claudicants and 41.4 ± 11.2% for patients with CLTI ( p < 0.01). Conclusion: The pave-and-crack technique is feasible for highly calcified femoropopliteal CTOs, achieving high technical success, encouraging long-term freedom from TLR, and high limb salvage. Graphical Long-Term Outcomes of the “Pave-and-Crack” Technique for Severely Calcified Femoropopliteal Chronic Total Occlusions. (Left) Lesion and Procedural Characteristics. (Middle) the “Pave-and-Crack” Technique (A) Fluoroscopy showing aggressive balloon pre-dilatation. (B) Angiography showing vessel rupture. (C) Fluoroscopy following covered stent implantation (Viabahn) and relining with an interwoven nitinol stent (Supera). (D) Final angiography. (Right) Kaplan Meier survival curves and estimates for freedom from target lesion revascularization over five years stratified for popliteal involvement (segment P1-P3). CLTI: Chronic limb threatening ischemia. CTO: Chronic total occlusion. PACSS: Peripheral Calcification Scoring System. PTA: Percutaneous transluminal angioplasty. KM: Kaplan-Meier, SD: Standard deviation, TLR: Target lesion revascularization.
Background/Objectives: Our aim was to assess the feasibility of hyperspectral imaging (HSI) to detect changes in tissue oxygenation (StO2) of the back, as non-invasive spinal cord collateral network (CN) monitoring during staged endovascular repair (ER) of thoracoabdominal aortic aneurysm (TAAA). Methods: Between September 2019 and June 2021, 20 patients were treated for TAAA and underwent HSI. They were randomized 1:1 to minimally invasive staged segmental artery coil embolization (MIS2ACE) (n = 10) and staged stentgraft implantation (n = 10) as priming methods. HSI of paravertebral regions was taken during each procedure and up to 10 days after. The primary endpoint was the identification of StO2 changes after ER of TAAA. Results: TAAA Crawford Type II (n = 17) and Type III (n = 3) were treated. After stentgrafting, StO2 increased immediately (p < 0.001), followed by a decrease after 5 days (p < 0.001) and 10 days (p = 0.028). StO2 was significantly higher in the thoracic compared to the lumbar region. There was no significant difference between MIS2ACE and the first stentgrafting for StO2 (p = 0.491). Following MIS2ACE, definitive ER caused a significant decrease in StO2 after 5 days (p = 0.021), which recovered to baseline after 10 days (p = 0.130). After stentgraft priming, definitive ER caused a significant decrease in StO2 after 24 h (p = 0.008), which did not return to baseline after 5 (p < 0.001) and 10 days (p = 0.019). Conclusions: HSI detected significant changes in StO2 in the thoracic and lumbar paravertebral regions during ER of TAAA. These preliminary data suggest the efficacy of MIS2ACE in priming the CN before ER of TAAA.
12 January 2026 in JACC: Cardiovascular Interventions